Recently, the class 1 innovative drug Keverprazan Hydrochloride Tablets of Jiangsu Carephar Pharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for treating duodenal ulcer and reflux esophagitis.

　　The Keverprazan Hydrochloride is a new potassium-competitive acid blocker, which inhibits gastric acid secretion by combining with the K+binding site on H+-K+-ATPase. The marketing of this drug provides a new treatment option available for patients with duodenal ulcer and reflux esophagitis.